Literature DB >> 26747643

Serum metabolomics strategy for understanding pharmacological effects of ShenQi pill acting on kidney yang deficiency syndrome.

Yang Nan1, Xiaohang Zhou1, Qi Liu1, Aihua Zhang1, Yu Guan1, Shanhua Lin1, Ling Kong1, Ying Han1, Xijun Wang2.   

Abstract

Kidney yang deficiency syndrome, a diagnostic pattern in Chinese medicine, is similar with clinical features of the glucocorticoid withdrawal syndrome. The aim of this present study was to explore low molecular mass differentiating metabolites between control group and model group of kidney yang deficiency rats induced with corticosterone as well as the therapeutic effect of Shen Qi Pill, a classic traditional Chinese medicine formula for treating Kidney yang deficiency syndrome in China. This study utilized ultra-performance liquid chromatography coupled with electrospray ionization synapt quadrupole time-of-flight high definition mass spectrometry (UPLC/ESI-SYNAPT-QTOF-HDMS) to identify the underlying biomarkers for clarifying mechanism of Shen Qi Pill in treating Kidney yang deficiency syndrome based on metabolite profiling of the serum samples and in conjunction with multivariate and pathway analysis. Meanwhile, blood biochemistry assay and histopathology were examined to identify specific changes in the model group rats. Distinct changes in the pattern of metabolites were observed by UPLC-HDMS. The changes in metabolic profiling were restored to their baseline values after treatment with Shen Qi Pill according to the combined with a principal component analysis (PCA) score plots. Altogether, the current metabolomics approach based on UPLC-HDMS and orthogonal projection to latent structures discriminate analysis (OPLS-DA) demonstrated 27 ions (18 in the negative mode, 9 in the positive mode, 17 ions restored by Shen Qi Pill). These results indicated that effectiveness of Shen Qi Pill in Kidney yang deficiency syndrome rats induced a substantial change in the metabolic profiles by regulating the biomarkers and adjusting the metabolic disorder. It suggested that the metabolomics approach was a powerful approach for elucidation of pathologic changes of Chinese medicine syndrome and action mechanisms of traditional Chinese medicine.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Biomarkers; Kidney yang deficiency syndrome; Metabolites; Metabolomics; Pattern recognition approaches; Shen Qi pill; UPLC–ESI–Q–TOF–HDMS

Mesh:

Substances:

Year:  2015        PMID: 26747643     DOI: 10.1016/j.jchromb.2015.12.004

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  36 in total

1.  High-throughput liquid chromatography mass-spectrometry-driven lipidomics discover metabolic biomarkers and pathways as promising targets to reveal the therapeutic effects of the Shenqi pill.

Authors:  Wen-Xiu Li; Ai-Hua Zhang; Xiao-Hang Zhou; Yang Nan; Qi Liu; Hui Sun; Heng Fang; Xi-Jun Wang
Journal:  RSC Adv       Date:  2020-01-13       Impact factor: 4.036

2.  High-throughput lipidomics reveal mirabilite regulating lipid metabolism as anticancer therapeutics.

Authors:  Hong-Lian Zhang; Ai-Hua Zhang; Xiao-Hang Zhou; Hui Sun; Xiang-Qian Wang; Liu Liang; Xi-Jun Wang
Journal:  RSC Adv       Date:  2018-10-18       Impact factor: 4.036

3.  High-throughput chinmedomics-based prediction of effective components and targets from herbal medicine AS1350.

Authors:  Qi Liu; Aihua Zhang; Liang Wang; Guangli Yan; Hongwei Zhao; Hui Sun; Shiyu Zou; Jinwei Han; Chung Wah Ma; Ling Kong; Xiaohang Zhou; Yang Nan; Xijun Wang
Journal:  Sci Rep       Date:  2016-12-02       Impact factor: 4.379

4.  Insight into the metabolic mechanism of scoparone on biomarkers for inhibiting Yanghuang syndrome.

Authors:  Heng Fang; Aihua Zhang; Jingbo Yu; Liang Wang; Chang Liu; Xiaohang Zhou; Hui Sun; Qi Song; Xijun Wang
Journal:  Sci Rep       Date:  2016-11-21       Impact factor: 4.379

5.  A Metabolomics-Based Strategy for the Mechanism Exploration of Traditional Chinese Medicine: Descurainia sophia Seeds Extract and Fractions as a Case Study.

Authors:  Ning Zhou; Ya-Ping Sun; Xiao-Ke Zheng; Qiu-Hong Wang; Yan-Yun Yang; Zhi-Yao Bai; Hai-Xue Kuang; Wei-Sheng Feng
Journal:  Evid Based Complement Alternat Med       Date:  2017-08-28       Impact factor: 2.629

6.  Screening the active compounds of Phellodendri Amurensis cortex for treating prostate cancer by high-throughput chinmedomics.

Authors:  Xian-Na Li; Aihua Zhang; Meijia Wang; Hui Sun; Zhidong Liu; Shi Qiu; Tianlei Zhang; Xijun Wang
Journal:  Sci Rep       Date:  2017-04-06       Impact factor: 4.379

7.  Jinkui Shenqi Pills Ameliorate Asthma with "Kidney Yang Deficiency" by Enhancing the Function of the Hypothalamic-Pituitary-Adrenal Axis to Regulate T Helper 1/2 Imbalance.

Authors:  Bing Ji; Yuan-Yuan Li; Wei-Ji Yang; Li-Zong Zhang; Ming-Sun Fang; Hui-Ying Fu; Qi-Yang Shou
Journal:  Evid Based Complement Alternat Med       Date:  2018-02-08       Impact factor: 2.629

8.  Plasma Metabolomics Analysis Based on GC-MS in Infertile Males with Kidney-Yang Deficiency Syndrome.

Authors:  Piao Zheng; Yun Wang; Hongmei Lu; Xinyi Zhou; Tao Tang; Rong Fan; Chunhu Zhang; Hanjin Cui; Yang Wang; Jiekun Luo
Journal:  Evid Based Complement Alternat Med       Date:  2017-09-25       Impact factor: 2.629

9.  The mechanism of blood concentrations of the Shenqi pill repairing injured epithelial cells of renal tubular in vitro.

Authors:  Fei Huang; Wenfeng Ma
Journal:  Exp Ther Med       Date:  2017-05-11       Impact factor: 2.447

10.  Metabolic characterization and pathway analysis of berberine protects against prostate cancer.

Authors:  Xianna Li; Aihua Zhang; Hui Sun; Zhidong Liu; Tianlei Zhang; Shi Qiu; Liang Liu; Xijun Wang
Journal:  Oncotarget       Date:  2017-04-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.